Sodium-Glucose Cotransporter 2 Inhibitors.e932 Mineralocorticoid Receptor Antagonists (MRAs).e931 Renin-Angiotensin System Inhibition With ACEi or ARB or ARNi.e928 Management of Stage C HF: Activity, Exercise Prescription, and Cardiac Rehabilitation.e926ĭiuretics and Decongestion Strategies in Patients With HF.e927 Management of Stage B: Preventing the Syndrome of Clinical HF in Patients With Pre-HF.e921 Patients at Risk for HF (Stage A: Primary Prevention).e919
#MORTAL KOMBAT PROJECT 4.1 STAGE TRANSITIONS OFF SERIAL#
Initial and Serial Evaluation: Clinical Assessment: HF Risk Scoring.e918 Wearables and Remote Monitoring (Including Telemonitoring and Device Monitoring).e916Įxercise and Functional Capacity Testing.e917 Use of Biomarkers for Prevention, Initial Diagnosis, and Risk Stratification.e911 Initial Laboratory and Electrocardiographic Testing.e910 Organization of the Writing Committee.e899Ĭlass of Recommendation and Level of Evidence.e900Ĭlassification of HF by Left Ventricular Ejection Fraction (LVEF).e901ĭiagnostic Algorithm for Classification of HF According to LVEF.e905Ĭlinical Assessment: History and Physical Examination.e908 , MD, PhD, FACC, FAHA, FHFSA, Vice Chair, Customer Service and Ordering InformationĢ022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 kommentar(er)
